Central-acting aminopeptidase a inhibitors for new treatment of hypertension: from discovery to clinical trial.

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Reda Hmazzou

Paris (France)

14 More presentations in this session

Presentation thumbnail

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase

Doctor K. Bapatla (Hyderabad, IN)

Abstract Slides

Presentation thumbnail

Thrombin generation and platelet function in patients on RAAS inhibitors

Doctor C. Helten (Duesseldorf, DE)

Presentation thumbnail

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Doctor E. Chowdhury (Perth, AU)

Abstract Slides

Presentation thumbnail

Hemodynamic management of resistant hypertension

Doctor F. Chacon-Lozsan (Budapest, HU)

Abstract Slides

Presentation thumbnail

Assess of angiotensin receptor blockers therapy associated to mineralocorticoid receptor antagonists or to calcium channel blockers plus hydrochlorothiazide according central haemodynamic parameters

Doctor C. Paterno Marchioli (Castiglion Fiorentino (AR), IT)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 5 - Hypertension treatment: drugs and devices

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

RNA therapeutics for treatment of hypertension

Congress Presentation

The floor is yours: bring your questions about optimal blood pressure control for organ protection - expert panel

Congress Presentation

Aldosterone-targeted therapies in hypertension

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources